Overview

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Status:
Unknown status
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.
Phase:
Phase 4
Details
Lead Sponsor:
ikfe-CRO GmbH
Collaborator:
IKFE Institute for Clinical Research and Development
Treatments:
Insulin
Insulin Glargine
Insulin glulisine
Insulin, Globin Zinc
Insulin, Isophane
Isophane insulin, beef
Isophane Insulin, Human